MX2021005236A - Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. - Google Patents
Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.Info
- Publication number
- MX2021005236A MX2021005236A MX2021005236A MX2021005236A MX2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- tigit antibody
- dosing regimen
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a regímenes de dosificación de un anticuerpo anti-TIGIT útil para el tratamiento de cáncer. En particular, la invención se refiere al régimen de dosificación en una terapia de combinación que comprende administrar un anticuerpo de una proteína de muerte programada 1 (PD-1) o del ligando 1 de muerte programada (PD-L1) y un anticuerpo anti-TIGIT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862755805P | 2018-11-05 | 2018-11-05 | |
PCT/US2019/059581 WO2020096915A1 (en) | 2018-11-05 | 2019-11-04 | Dosing regimen of anti-tigit antibody for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005236A true MX2021005236A (es) | 2021-06-18 |
Family
ID=70611082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005236A MX2021005236A (es) | 2018-11-05 | 2019-11-04 | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210403557A1 (es) |
EP (1) | EP3877418A4 (es) |
JP (1) | JP2022512851A (es) |
KR (1) | KR20210091209A (es) |
CN (1) | CN113302204A (es) |
AU (1) | AU2019375409A1 (es) |
BR (1) | BR112021008582A8 (es) |
CA (1) | CA3118964A1 (es) |
MX (1) | MX2021005236A (es) |
WO (1) | WO2020096915A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2279412T3 (pl) | 2008-04-09 | 2017-12-29 | Genentech, Inc. | Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
KR20230024368A (ko) * | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
EP4219553A1 (en) * | 2020-09-22 | 2023-08-02 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-tigit antibody and double antibody and their application |
WO2023018675A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
WO2023018677A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014149425A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TN2017000024A1 (en) * | 2014-08-19 | 2018-07-04 | Merck Sharp & Dohme | Anti-tigit antibodies. |
PT3283107T (pt) * | 2015-04-17 | 2020-08-31 | Bristol Myers Squibb Co | Composições compreendendo uma combinação de ipilimumab e nivolumab |
US20210363243A1 (en) * | 2018-02-01 | 2021-11-25 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
-
2019
- 2019-11-04 US US17/288,641 patent/US20210403557A1/en active Pending
- 2019-11-04 AU AU2019375409A patent/AU2019375409A1/en active Pending
- 2019-11-04 JP JP2021523335A patent/JP2022512851A/ja active Pending
- 2019-11-04 EP EP19881474.1A patent/EP3877418A4/en active Pending
- 2019-11-04 WO PCT/US2019/059581 patent/WO2020096915A1/en unknown
- 2019-11-04 KR KR1020217017162A patent/KR20210091209A/ko unknown
- 2019-11-04 BR BR112021008582A patent/BR112021008582A8/pt unknown
- 2019-11-04 CA CA3118964A patent/CA3118964A1/en active Pending
- 2019-11-04 MX MX2021005236A patent/MX2021005236A/es unknown
- 2019-11-04 CN CN201980087763.5A patent/CN113302204A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020096915A1 (en) | 2020-05-14 |
EP3877418A4 (en) | 2022-08-17 |
JP2022512851A (ja) | 2022-02-07 |
BR112021008582A8 (pt) | 2023-02-07 |
CA3118964A1 (en) | 2020-05-14 |
EP3877418A1 (en) | 2021-09-15 |
CN113302204A (zh) | 2021-08-24 |
BR112021008582A2 (pt) | 2021-08-10 |
US20210403557A1 (en) | 2021-12-30 |
AU2019375409A1 (en) | 2021-05-27 |
KR20210091209A (ko) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
PH12019500270A1 (en) | Combination therapy for cancer | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
CY1123993T1 (el) | Μεθοδος αγωγης καρκινου χρησιμοποιωντας αναστολεα σημειων ελεγχου ανοσιακου• αντισωμα που δεσμευεται σε υποδοχεα προγραμματισμενου θανατου-1 (pd-1) ή προσδετη 1 προγραμματισμενου θανατου (pd-l1) | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MY195474A (en) | Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1) | |
PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
MX2021006786A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
MX2019006072A (es) | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). | |
PH12017501857A1 (en) | Pd-l1 antagonist combination treatments | |
MX2022005618A (es) | Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1). | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
EA201990530A1 (ru) | Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака | |
WO2018102589A3 (en) | Anti-hrs antibodies and combination therapies for treating cancers | |
MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
MX2020009743A (es) | Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos. | |
BR112017011538A2 (pt) | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) | |
MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
MX2021004226A (es) | Terapia combinada contra el cáncer. | |
MX2021005266A (es) | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. |